4D Molecular Therapeutics Inc. (FDMT) News
Filter FDMT News Items
FDMT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FDMT News Highlights
- For FDMT, its 30 day story count is now at 2.
- Over the past 17 days, the trend for FDMT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AGE, AMD and COLL are the most mentioned tickers in articles about FDMT.
Latest FDMT News From Around the Web
Below are the latest news stories about 4D MOLECULAR THERAPEUTICS INC that investors may wish to consider to help them evaluate FDMT as an investment opportunity.
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMDDesignation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular degeneration (wet AMD) 4D-150 is the first therapeutic candidate to receive either RMAT or Breakthrough Designation for wet AMDRMAT designation follows Priority Medicines (PRIME) designation received from the European Medicines Agency (EMA) in October 2023Receiving both RMAT and PRIME enables increased coll |
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 ConferenceInitial interim landmark data analysis (N=50 at 24 Weeks) to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, on Saturday, February 3, 2024 at 4:20 p.m. ET EMERYVILLE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that the initial interim l |
4DMT to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, 4DMT, or the Company), a genetic medicines company with three novel, highly targeted next generation AAV vectors currently in human clinical studies, announced today that management will participate in a fireside chat at an upcoming investor conference in November. Members of the management team will also be available for one-on-one meetings in connection with this meeting. 6th Annual Evercore IS |
Broker Revenue Forecasts For 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Are Surging HigherShareholders in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) may be thrilled to learn that the analysts have just... |
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportA week ago, 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) came out with a strong set of third-quarter numbers that... |
4DMT Reports Third Quarter 2023 Financial Results and Operational HighlightsRapidly advanced 4D-150 development for wet age-related macular degeneration (wet AMD): completed enrollment of PRISM Phase 2 Dose Expansion nearly two quarters earlier than expected and enrolled first patient in Population Extension cohortInterim data update from 4D-150 PRISM Phase 2 Dose Expansion (n=50; high anti-VEGF need patients) in wet AMD expected in early 2024; update on FDA feedback on Phase 3 pivotal trial plans expected in Q1 2024Received European Medicines Agency’s Priority Medicine |
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFCAerosolized 4D-710 was generally well tolerated with no inflammation in any lung biopsy across Cohorts 1 and 2 (1E15 & 2E15 vg; n=7) with up to 17 months follow-upPromising, reproducible, CFTR expression significantly above normal levels across all participants and all lung tissue samples collected (n=34), substantially exceeding target profileDurable clinical activity demonstrated by improvements in quality of life by CFQ-R-RD and pulmonary function by ppFEV1 through 12 months in Cohort 1FDA fe |
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease CardiomyopathyInitiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic syndrome (aHUS) associated with intravenous (IV) AAV dosing, including addition of R/S immunosuppressive regimen4D-310 combines a novel, targeted next generation AAV vector (C102) and GLA transgene for a single low dose IV delivery to cardiomyocytesInterim clinical data from INGL |
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Microsoft upgraded, F5 Networks downgraded: Wall Street's top analyst callsMicrosoft upgraded, F5 Networks downgraded: Wall Street's top analyst calls |